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ABSTRACT 
Advances concerning the hosts’ immune response to M. leprae infection have focused on 
elucidating the immune patho-mechanism(s) involved with the hope that predictive diagnostic 
and prognostic parameters (biomarkers) for field use would emerge. However, improvements in 
our understanding of the immunological responses to this complex disease have to date 
somewhat failed to provide the effective and robust methods for improving its predictive 
diagnosis in the field situation, particularly in those patients suffering from paucibacillary disease. 
In this article we have attempted to review some of the advances both in the immunology and 
immunopathology of leprosy and also highlight the limited clusters of immune parameters which 
are now available. Most importantly, we point out the limitations that still prevail in the provision 
of effective biomarkers in the field situation for either: (i) the diagnosis of indeterminate disease, 
(ii) predictive diagnosis of individuals developing reactional states, (iii) monitoring efficacy of 
treatment or (iv) monitoring treatment of reactional states. 
  
PREFACE 
Leprosy is one of the oldest recorded diseases to affect mankind. Archeological studies 
have revealed evidence of leprosy in an Egyptian skeleton of the 2nd century BC and the earliest 
written records, dating back to 600 B.C., come from India.
1
 Interestingly, in the American 
continent the disease seems to be more recent as was most likely imported from Europe.
2
 The 
stigma about leprosy prevails to these days because the close relationship between patients and 
new cases and the fact that M. leprae is not observed in healthy individuals.
3
  
Although the Koch’s postulates established a causative link between the presence of a 
microorganism and the associated disease, Mycobacterium leprae continues to defy this postulate. 
The presence of M. leprae in leprosy lesions discovered by Hansen in 1873 has lead to the 
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concrete evidence that the disease is associated with an infectious agent but experimental studies 
have failed to demonstrate the full human disease in animal models.
3
 Moreover, the characteristic 
of M. leprae of being non-cultivable in vitro added to the absence of experimental models, has 
proven to be a major hurdle in the elucidation of the pathology of leprosy.  
Despite some contrary observations
4
, it is a widely recognized that this unique spectral 
disease results from the complex manifestations of varied immune responses that occur in 
different individuals susceptible to the same organism (M. leprae). One of the remarkable 
features of the disease is that the majority of individuals exposed to M. leprae remain normal and 
healthy and <10% of infected individuals succumb to the full-blown disease. 
Another unique characteristic of M. leprae is its affinity for the Schwann cells of 
peripheral nerves, probably either as an evasive mechanism by the bacteria to avoid host 
immunity or on account of it being a favorable microenvironment, supporting bacterial growth  
This facilitates the slow but sure progression of nerve impairment, until the immune system 
recognizes the bacteria and the subsequent inflammatory response destroys the nerve further, the 
major single cause of leprosy associated impairment.  
On account of the long incubation period of M. leprae within a host, the population at 
large, particularly in endemic areas, must be kept under constant surveillance. A pressing need 
for the containment of the disease in this millennium, is establishing predictive diagnostic and 
prognostic biomarkers for the infection and its complications (reactional states). 
     A surge of research particularly concerning the hosts’ immune response has focused 
on elucidating the immune pathomechanism(s) with the hope that predictive diagnostic and 
prognostic parameters (biomarkers) will emerge. Hence, the advances in leprosy immunology 
that we describe in the following paragraphs are rather the application of increasing 
immunological knowledge about the disease rather than the immunology of leprosy. This 
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exercise is also an attempt to elucidate the immunity of patients versus those “immune” 
individuals who have been exposed to infection but do not develop overt disease (asymptotic).  
 
ADVANCES IN IMMUNOPATHOLOGY OF LEPROSY AND LIMITATION  
 
1) Ridley & Jopling classification and the advancing immunological concept  
The Ridley & Jopling classification of leprosy is based on the manifestation of varying 
proportion of cellular infiltrates in lesions of different patients. The dynamic changes in lesional 
cellular infiltrates in combination with the clinical appearance of the lesions gave rise to the 
spectral concept of the disease.
5
 The lepromatous leprosy (LL) pole shows multiple, 
symmetrically distributed lesions, showing an infiltrate largely composed of macrophages with 
varied degrees of foamy changes and few, scattered lymphocytes and plasma cells
6
; bacilli are 
numerous within and outside macrophages and many aggregate to form globi.
7
 Nerves may show 
some structural damage or enlargement but hardly any cellular infiltration or lymphocyte cuffing; 
the nerve destruction is gradual, slow and frequently unnoticed. In addition, Schwann cells, 
perineural cells, axons, intraneural macrophages of dermal nerves may also contain bacilli.  
On the other hand, tuberculoid leprosy (TT) shows few lesions with well-defined margins 
in which the center is markedly hypoaesthetic and does not show the presence of acid-fast 
bacteria. Lesional infiltrate primarily consists of foci of well-developed epithelioid macrophages, 
with or without Langhans’ type of multi-nucleated giant cells surrounded by a cuff of 
lymphocytes.
6
 Within the granulomas, small nerves may be destroyed beyond recognition and a 
thickened peripheral nerve is regularly palpable in the vicinity of a lesion.  
In between the two polar leprosy types are the unstable borderline forms including 
borderline lepromatous (BL), mid-borderline (BB) and borderline tuberculoid (BT), showing 
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clinical and histopathological characteristics intermediate to the polar forms. BT patients present 
several anesthetic and granulomatous lesions with cellular pattern similar to that are seen in TT 
patients but may contain a few bacilli. In BB patients, lesions are intermediate in number and size 
between tuberculoid and lepromatous patients with moderate anesthesia and irregular form; they 
are composed of epithelioid cells and lymphocytes diffusely spread while giant cells are absent 
and a bacilloscopic index (BI) of 3 or 4+ is regularly found. BL patients usually present 
numerous lesions sometimes hypoesthetic in some parts composed of histiocytic cells that tend to 
evolve to epithelioid cells, lymphocytes are scanty and a BI of M. leprae may be seen.
5
 
A significant proportion of the leprosy patients, especially borderline ones, develop 
leprosy reactions either during the course of the disease or even after the multi-drug therapy 
(MDT).
8-10
 Reactions are thought to be immune exacerbations as can be postulated from the 
changes in the characteristic proportion of lymphocytes to histiocytes and interpreted due to the 
lymphocytic reactivities to M. leprae and its antigens.
11
 Principally two types of reactions are 
seen: i) type 1 or reversal reaction (RR) localized to dermal patch and neighboring nerves 
showing acute increase in both matured and blast lymphocytes most likely being M. leprae 
specific indicating an increase specific cell mediated immunity accompanied by excessive release 
of Th1 cytokines in the tissue; ii) type 2 reaction or erythema nodosum leprosum (ENL) whose 
histopathology appears to be complex involving immune complex deposition in the vessel walls
12
 
and later in the tissues
13
, besides the fluctuation of T cell immunity also plays important role. The 
main features of reactions are summarized in BOX 1 and 2. 
 
2) Immunopathology for further refinement of spectral pathology of leprosy 
Rees and coworkers using an experimental model of leprosy showed that the elimination 
of M. leprae within macrophages is mainly T cell-mediated.
14
 With this background, renewed 
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studies of the in situ characterization of the cellular infiltrates in leprosy lesions were undertaken. 
The availability of monoclonal antibodies aided the characterization of different cell populations 
and also immunohistochemical detection of cytokines/chemokines, enzymes and bacterial 
antigens within the tissues. These have served as confirmatory biomarkers of disease and as 
indicators of the spectral form of leprosy. For example, LL/BL lesions exhibit a characteristic 
infiltrate involving significant numbers of macrophages, B/plasma cells and scattered T cells, 
predominantly of the CD8
+
 subtype (Photomicrograph 1), in contrast to TT/BT lesions which 
exhibit primarily T cell infiltrates, mostly CD4
+
,
 
with little involvement of plasma cells, 
macrophages or CD8+ and regulatory T cells (Treg). Additionally, monoclonal antibodies against 
M. leprae antigens helped to optimize the differential diagnosis of leprosy
15,16
 even on formalin 
fixed tissues.
17
 With respect to the leprosy spectrum, LL/BL lesions exhibit strong expression of 
mycobacterial lipoarabinomannan (LAM) and the M leprae-specific phenolic glycolipid (PGL)-I 
antigens whereas TT/BT lesions exhibit much weaker staining. Importantly, the in situ detection 
of M .leprae antigens appears to be a confirmatory diagnosis of leprosy lesions even in the 
absence of bacilli. In addition, the differing expression pattern of these two antigens also 
identifies the reactional lesions as compared to the non reactional lesions
.16
 
Further characterization also revealed that LL/BL skin lesions exhibit decreased numbers 
of CD1a
+
 Langerhans cells in the epidermis as compared to BT/TT lesions.
18
 In this context, it is 
worth mentioning that the expression of a secretory antigenic epitope recognized by the 
monoclonal antibody 3A8 on CD1a epidermal LC clearly identifies RR lesions.
19
 
In addition to immunohistopatholgy, molecular technology like polymerase chain reaction 
(PCR) for measuring mRNA of cytokines within the granuloma of the lesions from leprosy 
patients across the spectrum showed an improved classification of leprosy pathology.
20,21
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Moreover, techniques like T cell cloning or flow cytometry using CD markers help to 
isolate T cell subsets from blood or lesions to characterize their cytokine profile and association 
with leprosy spectrum and reactional episodes.
20,22,23
 Taken together with the cumulative results 
of immunopathological analysis, as reported in literature, the Ridley Jopling’s original 
classification of leprosy and reaction can now be modified as depicted in the Figure 1.   
It should be, however, emphasized that such approach will need at least the facilities of 
modestly equipped laboratory.   
 
A BRIEF OUTLINE ON ADVANCES OF IMMU OLOGY 
The preceding discussion demonstrates that a basic understanding of immunology is 
important in interpreting the pathology of leprosy and reactions. Briefly, the immune response is 
characterized by the innate immune response providing the first line of defense against pathogens 
and the acquired or adaptive immune response which is the antigen-specific arm.  
 
1) Innate arm of immune response 
Apart from mechanical and chemical barriers, the innate immune response consists of 
cells such as the polymorphonuclear leucocytes (PMN) and the monocyte/macrophage lineage 
which use pattern recognition receptors (PRR) to recognize pathogen-associated molecular 
patterns (PAMPs), evolutionarily conserved and widely distributed among different classes of 
pathogens. Among the important PRRs are the Toll-like (TLR), NOD-like (NLR) and C-type 
lectin (CLR) receptor families. Engagement of PRR by PAMPS results in activation of specific 
signal transducing systems within the host cells resulting in the release of pro- and anti-
inflammatory mediators. At the same time, release of chemokines help to recruit lymphocytes 
and PMNs in order to sequester and eliminate the organism via inflammation and by releasing 
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enzymes, free radicals and other cytokines.
24
 Another important component of innate immunity is 
complement activation, which is also implicated recently in the pathology of leprosy spectrum 
and reactions.
25
 The presently recognized paradigm of innate immunity applicable to leprosy is 
summarized in Figure 2. For complete immunologic description the readers are also advised to 
refer to an article by Nath et al. in the previous issue. 
 
2)  Acquired arm of immune response 
The acquired immune response starts with dendritic cells (DCs), potent antigen presenting 
cells (APC), which function as a bridge between innate and acquired arms of the immunity. DCs 
migrate from the site of infection and present antigen to naïve T-cells within the regional lymph 
node. Depending on their degree of maturation and signals (in terms of co stimulation and 
cytokines), DCs can stimulate naïve T cells to differentiate into distinct effector subpopulations.   
CD4+ T cells are the dominant players in both the induction and effector phases of the 
immune response. On antigen engagement by their T cell receptors (TCRs), they can differentiate 
into (i) T helper 1 (Th1), secreting interleukin-2 (IL-2) and interferon-gamma (IFN-) and 
resulting in macrophage activation; (ii) T helper 2 (Th2) cells, secreting interleukin-4 (IL-4), 
interleukin-5 (IL-5) and interleukin-13 (IL-13) which stimulates the production of antibodies and 
inhibits macrophage activation
26
; or (iii) into T helper 17 cells (Th17) that produces interleukin-
17 (IL-17) and interleukin-22 (IL-22) and are involved in inflammation and autoimmunity.
27
 
Further the activities of resulting repertoire of antigen specific Th1 and Th2 cells appear to be 
under the control of another subset set of CD4+CD25+ FOXP3+, interleucina-10 (IL-10) or 
transforming growth factor beta (TGFβ)+ T cells known as Treg.28,29 
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  Usually antigen specific T cells are recruited together with macrophages and DC in a 
lesion and form different types of granuloma which are modulated by different cytokines during 
the evolution of the disease, giving rise to a spectral disease as seen in leprosy. The basic 
mechanism of granuloma formation and its modulation is summarized in Figure 3.  
 
THE EVOLUTION OF DIAGNOSTIC TOOLS FOR LEPROSY  
 
1) Cell-mediated immunity and skin reactivity in leprosy – Mitsuda test 
An important tool in measuring specific cell-mediated immunity in leprosy is lepromin, a 
crude preparation of inactivated M. leprae homogenates, also known as Mitsuda reagent. The 
Mitsuda reaction is a robust skin test, which can discriminate between LL and TT patients. The 
reagent, prepared from highly bacilliferous LL lesions or from M. leprae infected armadillo tissue, 
is injected subcutaneously being examined 28 days later for signs of a  DTH reaction. To classify 
a patient the use of this skin test should be recommended as a primary, “stand alone” mode of 
definitive diagnosis of suspected paucibacillary (PB) leprosy cases and to make the diagnosis of 
PB leprosy highly likely in patients with slit-skin smear negativity and indeterminate histology 
but with a suspect cellular infiltrate and/or granuloma. A negative Mitsuda test can also aid in the 
confirmation of multibacillary (MB) disease where the patient presents with acid fast bacillus 
positive lesions and enlarged nerves. Some major disadvantages are its relative insensitivity, 
subjectivity of interpretation and lengthy response kinetics. There are also concerns about its 
contamination with animal material from which it was extracted, and batch variability in activity. 
However, in Brazil, lepromin reagent is routinely produced at the Institute of Lauro de Souza, 
Bauru, São Paulo. Lepromin and in vitro lymphoproliferative assay using patient PBMC (LpA) in 
presence of M. leprae antigens can thus aid in classification of patients in the leprosy spectrum. 
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2) Antibody titers in leprosy 
Although population presents circulating anti-mycobacteria antibodies due to 
environmental exposure to different Mycobacteria species, the search for a M. leprae-specific 
dominant antigen resulted in the demonstration of the species-specific phenolic glycolipid (PGL)-
I
30
 and paved the way for serological assays for detection of anti-PGL-I antibodies in the sera of 
patients. Anti-PGL-I IgM antibody is regarded to be highly specific and useful for leprosy 
diagnostic as well as valuable in monitoring the contacts that might be at risk of developing the 
disease.
31-35
 While the advantage of the use of PGL-I serology is its relatively high specificity, up 
to 90% in various studies
36-38
, the major drawback is its lack of sensitivity in the detection of PB 
patients
36-39
 and also in assessing the clinical status of those patients.
40
 
The use of anti PGL-I serology has been simplified by the development of a rapid 
immunochromatographic flow test (ML-Flow test) as a simple dipstick assay even using whole 
blood samples. The ML flow test has been shown to be comparable to the ELISA in its 
sensitivity, being able to detect >90% of MB patients and 40% of PB patients, with background 
seropositivity in endemic controls at around 10% (31). Moreover, the dipstick test was reported 
to be applicable in the field, identifying multibacillary patients without the need for a slit-skin 
smear test. However, the use of these tests have gradually declined due mainly to cost.
41
 It is our 
contention that such a simple test, a spin off product of advances in immunology is a useful tool 
that should be implemented in endemic regions for the control of transmission, on the 
understanding that it is the best assay we have, excluding good clinical assessment. 
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3) Cross reacting antigens and recombinant M. leprae antigens 
The differential host responses observed to immunologically cross-reactive antigenic 
components of mycobacteria (mycobacterial-ImCRAC) among individuals exposed to different 
mycobacteria has long been recognized
42-43
. Therefore several investigators have focused efforts 
on the development of diagnostic antibody assays for leprosy based on such mycobacterial cross-
reacting antigens, i.e. a “bar code” recognition system.44 
The antigen 85 complex (Ag 85) is known to be a dominant antigen in the immune 
response to all mycobacterial species.
45,46
 Despite the cross-reactivity, which restricts its utility as 
a specific marker in the diagnosis of leprosy, seropositivity for anti-Ag 85 components have been 
observed in 50-100% of lepromatous and 0-38% of tuberculoid leprosy patients.
47-49
 
Interestingly, the use of combination of native gel purified Ag 85 components and the 
mycobacterial heat shock protein 65kDa (hsp65) in an ELISA serology have been reported to be 
capable of differentiating LL from TT forms of the disease.
44,50
 
Further studies revealed that the sera of >90% of LL/BL patients and > 85% of TT/BT 
leprosy patients reacted strongly to mycobacterial (29/33kDa doublet) and Hsp 65 (64-65kDa 
singlet) antigen fractions in Western blot assays (WB) combined with ELISA. The ImCRAC 
signature on WB by leprosy patient sera against whole mycobacterial antigen was found to be 
disease-specific.
44,47
  Moreover the WB could be used to discriminate between TT, BT, BL or LL 
forms of leprosy. These candidate antigens have subsequently been purified from SDS-
electrophoretic gels and used in an ELISA format, but unfortunately the ELISA could neither 
identify reactional patients nor monitor patient antibody responses to MDT since these antibodies 
appear to have a long half-life. The full potential of these surrogate markers merits further 
investigation for uses in combination with anti-PGL-I (IgM) and another assays using 35kDa.
51
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Most leprosy patients and contacts, but not TB patients, showed T cell proliferation or 
IgG response to the 35kDa protein of M. leprae
52,53
 demonstrating its specificity. In both ELISA 
and dipstick assays, a relatively high sensitivity was obtained for both MB (70-100%) and PB 
(40-60%) of leprosy patients.
54-56
 However, anti-PGL-I assays were found to be more specific
56
 at 
least in MB and, in cases of PB its applicability appeared to be controversial. Another approach 
using Ag 85 detection of the antigen in the sera of leprosy patients was investigated
57
. A ratio of 
Ag85 to circulating 65kDa levels was then proposed as being indicative of the presence of viable 
M. leprae in patients, based on a similar approach adopted in TB diagnosis.
58
 However, the low 
sensitivity for Ag 85 in the sera of untreated MB patients limited it potential use for monitoring 
leprosy patients.
57
 
Various investigators have also attempted to use recombinant biotechnology to produce 
different antigens from the Ag 85 complex and to test these recombinant proteins for measuring 
both leprosy-associated antibody and T cell responses. However, T cell responses were not found 
to be useful to leprosy diagnostic or prognostic, whereas high antibody levels, to the different 
peptides or to the Ag 85 complex, were associated with MB but not with PB disease or reactional 
states. Therefore the use of the Ag 85 complex has not provided any major advance on other 
available leprosy associated dominant antigens particularly PGL-I. 
 
4) Further advances for discovering M. leprae specific antigens  
With the sequencing of the M. leprae genome
59
 new recombinant antigens with no known 
homologues emerged to provide potential improvements in the diagnostic tool box. Five of these 
antigens were subsequently shown to be able to recognize individuals exposed to M. leprae as 
assessed by IFN-γ release assay (IGRA). Their sensitivity was reported to be high, being able to 
detect 71% of healthy contacts not identified by PGL-I IgM serology. These reports indicated that 
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these antigens could be potential candidates for the diagnosis of leprosy.
60
 After, other proteins 
and peptides were tested for assessing immune response against M. leprae in order to develop 
adjuvant tool to evaluate exposure to leprosy or disease.
61-68
 
Although IgG antibody response to several of these proteins showed geographic variation, 
two proteins named ML0405 and ML2331 were largely recognized by serum of patients. Based 
on this, a chimeric fusion protein termed LID-1 (leprosy IDRI diagnostic 1) was constructed from 
overlapping sequences of these proteins.
69
 Positive titers of antibodies against LID-1 protein were 
found in 87 to 92% MB and 7 to 48% PB patients in different populations.
61,69,70
 Of special 
interest was that some individuals presented high titers of antibodies against LID-1 one year 
before the appearance of clinical symptoms of leprosy
69
 suggesting a role of this protein in the 
monitoring of contacts. Interestingly, LID-1 can also be used in a cell-based IGRA assay to 
determine the cell-mediated immune status as in case of the “Quantiferon” assay for TB.71 
However, when the antibody assay using LID-1 and PGL-I in parallel was carried out the results 
were more or less similar (Unpublished data). Consequently, a new study brings nine more new 
hypothetical unknown proteins with potential to leprosy diagnostic based seroreactivity.
72 
However, the potential of these proteins should be evaluated in a larger casuistic and so the 
advances in the pursuit of new antigens using high throughput technology (HTPT) goes on but 
the gap between the fruits of these studies and field application remain as wide as before. 
 
5) Special focus on the complex pathology of leprosy reactions  
The preceding discussion demonstrates that laboratory-based immune tests concentrated 
on the diagnosis of leprosy. However, one of the major complications of leprosy is the associated 
reactional states, which occurs in a significant proportion of the patients. As a conservative 
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estimate, the incidence of reactions during the evolution of the disease could be in the range of 
20-30% of patients on treatment, which varies from country to country.  
The diagnosis of ENL lesions has been problematic for clinicians. Nath and coworkers 
addressed the question as to what causes a spontaneous development of an antigen-specific T cell 
response, during ENL in lepromatous patients who at diagnosis were Mitsuda LpA negative. 
Using a recombinant antigen LSR2 and its peptides, they reported that cryptic epitopes in the 
bacillus get exposed and recognized by the LL T cells only in ENL.
73
 More importantly, they 
showed that during ENL and prior to ENL the T cells recognized the sequences RGD, GVTY and 
NAA and these differ from the sequences of LSR2 recognized by the T cells of LL patients 
without ENL.
74-76
 Therefore, LSR 2 and its peptides can be used in an IGRA assay for ENL 
diagnosis. Unfortunately, these observations were not confirmed by other investigators yet.  
 
OTHER SEROLOGICAL AND IN SITU PARAMETERS: CYTOKINES, SOLUBLE 
CELL ACTIVATION MARKERS AND CHEMOKINES 
The generation and maintenance of immune cytokines and chemokines, which mediate 
multiple immunologic and non-immunological functions, are involved in the cross-talk between 
the different cells of the immune system. These molecules play a crucial role in the recruitment of 
the immune cells, the clonal expansion of lymphocytes as well as in the innate immune response 
and the effector response of most immune cells. These results in a complex fine-tuned regulatory 
network of cytokines which often determines the clinical course of the infection and the outcome.  
 
1) Cytokine cascades and roles in leprosy pathology and immunity  
With respect to leprosy, research has focused on the association of differential cytokine 
profiles with the spectral pathology.
20, 77, 78
 However, results from such studies have been varied 
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and conflicting and in retrospect it is difficult to associate distinct cytokine patterns with different 
spectral forms of leprosy or its reactions.
22,23,79-81
 
  Analyses of leprosy sera showed increased expression of cytokines, except IL-2 in all 
patients, IFN-in LL patients and IL-10 in TT patients, as compared to healthy controls82,83 
suggesting activation of the immune cells by M. leprae antigens in all leprosy patients. IFN- and 
TNF (tumor necrosis factor) were elevated in TT as compared to LL patients with a significant 
negative correlation with BI
82
  Besides, upon in vitro stimulation with M. leprae or its antigens a 
vast majority of the T cells recruited in tuberculoid leprosy are CD4+ with Th1 phenotype 
producing IFN-, IL-2 and TNF but little or no IL-4, IL-5 and IL-6.77, 84, 85 Furthermore, in vivo 
analyses evidenced mRNA for IFN-γ, IL-2, lymphotoxin (LT), TNF and Granulocyte-
macrophage colony-stimulating factor (GM-CSF).
20,78, 86
 LL patients, on the other hand, showed 
higher serum levels of IL-10 and interleukin-1 beta (IL-1β) as compared to TT patients.82 In vivo 
studies have demonstrated predominance of IL-4, IL-5 and IL-10 in LL lesions previously
20
 and 
also a positive correlation between IL-10 levels and BI (82). In our studies
21
 using 
immunohistochemistry and PCR in the same tissue specimen, we were not able to establish any 
clear cut cytokine profile specific for the spectral type of leprosy, as was found before.
20
 
Monitoring IFN- and IL-4 is valuable in evaluating the efficacy of the treatment and in the 
clinical management of reactions, since both cytokines declines during treatment.
21
 
    Consequently, several studies have been carried out to assess the validity of measuring 
serum cytokines for diagnosing and monitoring the leprosy spectrum and reactions. These studies 
have presented contradictory results with respect to the predominant cytokines involved, which 
may be related to the different assay conditions, samples and populations examined.
87,88
 
Moubasher et al.
82
 observed that while all leprosy patients showed elevated levels of IL-1β and 
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TNF as compared to healthy controls, some degree of differential expression was noted with 
IFN-γ and TNF being elevated in TT sera whereas the opposite response was seen with respect to 
IL-10 and IL-1β respectively. RR patients showed elevated levels of IFN- γ, IL-2R and IL-1β as 
compared to non-reactional patients liable to such reaction.
82, 89-91
 Whereas in ENL patients, in 
addition to the above mentioned cytokines, IL-10 levels were also elevated.
82, 84, 92
 Moreover, 
patients who developed reactions had significantly higher IL-1β levels as compared to those who 
did not, suggesting a prognostic value of IL-1β measurement in serum in predicting reactions.93 
In this context, our studies showed that cytokine profiling is useful in the diagnosis and 
monitoring of RR (TNF and IFN-γ) and IL-6/IL-IL-6 R for ENL.83, 87 
However it should be noted that the in situ analysis of cellular interaction and the 
cytokine/chemokine expression needs specialized laboratory facilities. 
 
2) Other soluble factors related to cellular activation 
Besides T cell cytokines, other indicators of cellular activation have been used as markers 
for CMI activity. The presence of neopterin that belongs to the class of pteridines in body fluids 
is suggested to be evidence for the activation of the CMI response, since its production is 
stimulated by IFN-γ (94). Elevated levels of serum neopterin were previously reported in 75% of 
leprosy patients including lepromatous (LL –BL) patients83 and in particular in reactions87,95 and 
could distinguish MB (LL-BL) from PB (BT) leprosy.
83,87
 It is paradoxical that the elevated 
neopterin, associated with increased IFN-γ production, is associated with lepromatous forms of 
leprosy suggesting that CMI response may not be completely defective in these patients.  
Human phagocyte-specific chitotriosidase, an endoglucosaminidase belonging to family 
18 of glycosylhydrolases, is an important component of the innate immune response.
96,97
 
Elevated serum chitotriosidase activity has been reported in malaria
98
, sarcoidosis
99
 and 
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tuberculous pleural effusions.
100
 In leprosy, chitotriosidase activity in serum was significantly 
elevated in LL/BL patients as compared to BT patients and healthy controls.
101
 ENL sera showed 
increased chitotriosidase activity as compared to healthy controls which declined after 
corticosteroid treatment. Moreover chitotriosidase activity correlated with levels of neopterin. 
Acute phase proteins (APP), which are systemic markers of inflammation, have been 
evaluated in leprosy and reactions. The most frequently assessed APPs include serum amyloid A 
(SAA) and C-reactive protein (CRP). Various studies have shown the limited value of CRP in 
identification or classification of non-reactional leprosy patients.
102-106
 With respect to SAA there 
are contradictory results with elevated levels reported in LL as compared to TT patients
102
, 
whereas other studies did not show a significant difference.
105,106
 However, ENL patients were 
unanimously shown to have elevated levels of SAA and CRP as compared to non- reactional 
LL/BL patients and controls suggesting their utility as biomarkers.
102,103,105,106
  
 
3) Chemokines in cell migration and tissue immunity in leprosy 
Chemokines are potent chemoattractants of leukocyte and play an important role in 
migration of effector cells. However, not much is known about the chemokine profiles in leprosy 
patients. Some of the early studies showed intense IP-10 expression by keratinocytes in TT 
lesions; LL lesions did not express IP-10 constitutively, however, administration of PPD or IFN-γ 
into these lesions resulted in a strong induction of IP-10 expression, suggesting a differential 
expression of IP-10 across the leprosy spectrum associated with IFN-γ expression (107). Kirkaldy 
et al.
108
 studied the expression of the chemokines MCP-1 (CCL2), RANTES and IL-8 (CXCL8) 
in leprosy lesions by in-situ hybridization (ISH). Although all chemokines were elevated, no 
differences in the level of expression were noted across the spectrum. However, MCP-1 and 
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RANTES were elevated in reversal reactions suggesting a role for these chemokines in migration 
and activation of the monocytes and T cells in these lesions.
108
 
In subsequent studies, MCP-1 and IL-8 were found to be elevated in serum in LL 
patients.
109,110
 Hasan et al.
111
 demonstrated elevated levels of MCP-1 in sera of LL patients as 
compared to healthy controls (EC) or pulmonary tuberculosis patients probably related to the 
dissemination of the disease. In contrast, RANTES levels were lower in the LL patients as 
compared to EC or tuberculosis patients suggestive of a shift away from the Th1 phenotype of 
these patients.
111
 Mendonça et al.
112
 reported elevated levels of only CCL3 (MIP-1α) and CCL11 
(Eotaxin) but not CCL2, CXCL9 or CXCL10 in leprosy patients as compared to non-infected 
individuals in a Brazilian population. They suggested the utility of CCL11 monitoring in plasma 
as an aid to the diagnosis of leprosy patients from non-infected populations.   
An important limitation of the use of cytokines, chemokines, acute phase proteins and 
cellular activation markers as biomarkers is that they reflect the general inflammatory response 
and would be expected to change in all immune-mediated conditions, thus they lack disease 
specificity. Hence such markers need to be combined with other indicators such as the anti-PGL-I 
titers, which are more disease specific, in addition to clinical and neurophysiological observations 
to obtain a more accurate and global view of the progression of the disease. However, these 
parameters may be of limited utility in monitoring treatment efficacy especially in reactional 
cases thus, probably, reducing the consequences of incomplete treatment. 
 
4) Other innate and acquired immunity related molecules 
i)  Complement 
The activation of complement results in the assembly of the membrane-attack complex 
(MAC), forming pores on the surface of the target cell and its eventual death.  Recently, we 
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observed that measurement of MAC complex in serum of leprosy patients could be of value as a 
prognostic tool
25
, since the preliminary studies showed that serum level of C9 and MAC are 
significantly elevated in reactional patients than those of no reactional individuals. However, but 
this pilot data needs confirmation. 
 
ii) Metabolomic and nutritional origins  
Since the exact mechanisms involved in disease susceptibility, onset and progression are 
presently unclear, recent research has focused on other aspects, including nutritional, genetic and 
metabolomic aspects associated with the disease. 
 
Fatty acids 
Various studies have examined lipid metabolism in leprosy, but there has been limited 
work using whole metabolite profiles to distinguish the clinical forms of leprosy. Some of the 
fatty acids are known, to have anti-inflammatory and others pro-inflammatory properties, and, 
could be potential markers for susceptibility and pathogenesis of the disease. In this regard, Al-
Mubarak  et al.
113
 reported higher levels of polyunsaturated fatty acids in lepromatous leprosy. A 
new  study
114
 revealed the metabonomic profile in leprosy patients showing an increase in the 
levels of omega-6 and omega-3 polyunsaturated fatty acids (PUFA) metabolites with anti-
inflammatory and pro-resolving roles in serum and skin during M. leprae infection, mainly in 
lepromatous patients, with normalization after multi-drug. The lipid profile observed suggests the 
development of host tolerance to the pathogen as a strategy to avoid tissue damaged.  
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Essential amino acid like tryptophan metabolizing enzyme 
A recent study
115
 reported the probable association of indoleamine 2, 3-dioxygenase 
(IDO) expression in LL macrophages with immunosuppression in lepromatous leprosy, using 
immunohistochemistry and serology. The authors concluded that IDO may be involved in the 
immunosuppressed status of LL patients in a pathogen-specific manner and may serve as an 
additional marker for the diagnosis and prognosis of the disease. 
 
Vitamin D and its metabolic enzymes 
It has long been appreciated that Vitamin D may influence the innate immunity against 
intracellular bacteria. Besides, the vitamin D-dependent induction of antimicrobial peptides in 
keratinocytes also provides a mechanism for host defense in skin.
116
 In leprosy, Montoya et al.
117
 
suggests that in TT patients infection with M. leprae triggers a protective vitamin D–mediated 
antimycobacterial innate immune response characterized by the generation of the antimicrobial 
peptides cathelicidin and DEFB-4. Conversely, in lepromatous leprosy it lacks activation of this 
Vitamin D mediated pathways and consequently occurs reduced expression of these defensins. It 
requires further investigation to determine whether any of these mediators can be utilized as 
biomarkers in the diagnosis of leprosy. 
 
The alpha1-acid glycoprotein  
Recent comparative analysis of the serum proteome of leprosy patients, highlighted the 
differential expression of the isoforms of the acute-phase protein alpha 1-acid glycoprotein 
(AGP).
118
 The same group reported that changes in serum levels of AGP and the differential 
expression of its isoforms can be used in the diagnosis and monitoring of ENL reactions, serving 
as a putative biomarker for ENL although the robustness of this association needs to be 
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established. Unfortunately, until to date, it remains unclear to what extent this marker is robust 
predictor and a marker for diagnosing ENL and monitoring the efficacy of the treatment. 
 
Nitric Oxide Synthase 
Nitric oxide generation is controlled by nitric oxide synthases which are regulated by 
IFN-, an important cytokine for leprosy immunity. The expression of nitric oxide synthases 
{inducible (i-NOS), endothelial specific (e-NOS) and neuronal specific (n-NOS) expressions was 
studied in leprosy spectrum and reactions, with the expectation of a better management of 
reactional patients. Although it has been reported in the literature that i-NOS expression could be 
used as a diagnostic marker for leprosy spectrum and reactions
119
 our own data could not confirm 
the findings as reported in literature.  
 
CONCLUDING REMARKS  
The preceding discussion shows that the application of immunological knowledge has 
aided the understanding of the complex pathology of leprosy. In the process, some molecular 
parameters which may be used as biomarkers of the disease have been identified. Indeed the list 
of such biomarkers is still growing whereas the robustness of these markers is still lacking. 
If we reflect back, it may be concluded that: 1) there is no “gold standard” for the 
diagnosis of leprosy per se and for the prediction of onset of reaction. The disease is still best 
diagnosed on the basis of clinical symptoms, slit-skin smear analysis and simple tissue histology. 
However, these criteria can be supported by the use of the PGL-I antibody assay and the Mitsuda 
test, which can be performed in the field situation. In the problematic “indeterminate” cases, 
molecular techniques such as: (i) immunohistochemistry, (ii) PCR and (iii) in situ hybridization 
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may prove useful in the detection of M. leprae specific antigens and genes. However these 
techniques can only be carried out in a well-equipped laboratory serving as referral centers. 2) 
There are still no “gold standard” biomarkers that could serve to predict leprosy reactions in 
although some insight has been gained. ENL is associated with high circulating levels of aAGP1, 
IL-6, IL-6R. The LSR2 specific T cell response and RR is associated increased levels of 
neopterin, TNF, CXCL10 and IFN-. These assay parameters again require reference laboratory 
facilities, although some commercial kits can be developed for determining a cluster of 
parameters in the field, but at a great cost. 3) Importantly considerable progress has been made in 
identifying candidate biomarkers for monitoring treatment efficacy in leprosy patients. Thus, 
further investigations of observed differences in the kinetics of anti PGL-I, LID-1 and LSR2 
responses between those who respond or do not respond to treatment are merited. 4) Progress has 
also been made in identifying disease associated inflammatory biomarkers which may prove 
useful for monitoring treatment of reactional states. These include; aAGP-1, IL-6 and IL-6R for 
ENL and neopterin, CXCL10 , IFN- ,TNF for reversal reactions.  
We therefore still have a long way to go in solving all the immunodiagnostic deficiencies 
associated with leprosy before we can look forward to assigning this disease to the history books. 
Good biomarkers can help clinicians in the diagnosis and monitoring of patients, at a time of 
declining numbers of clinical experts who previously could successfully diagnose and treat 
leprosy and its complications based on clinical symptoms and histopathological assessment. 
Some of the diagnostic problems with leprosy can be overcome by optimizing the 
collection of samples in the field and their transport to reference laboratories while investing 
efforts to develop simpler and more robust diagnostic/monitoring tests. Should we follow this 
path, it is hoped that disease transmission will be minimized by optimal determination of the end 
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point of treatment. In order to achieve such goals, the Public Health Authorities have to rethink 
their strategies for application of the evolving immunological markers for the management of 
patients suffering from leprosy. The other alternative is that the researchers will go on in the 
pursuit of high technology oriented approaches with contradictory results and with minimal 
benefit for the patients and clinicians. Sadly, it is our contention that the gap between advances in 
immunology and their field application remains a bridge too far at present but there is promise 
that the gap can be narrowed by using the available robust tools at hand. 
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Box 1: Reverse Reaction (RR) 
 
 More common in BB and BL patients as compared to BT patients. 
 
 Acute inflammation of skin and/or nerves: nerve function impairment.  
 
 Erythematous swelling of existing lesions, appearance of new lesions; onset or 
worsening of neuritis.  
 
 Lesions usually present increased infiltrate of lymphocytes, epitheloid cells, giant 
cells, oedema and a decrease in bacterial load and the immune response is 
characteristic of a delayed-type hypersensitivity (DTH). 
 
 Cell mediated immune process characterized by an increase in lymphoproliferative 
response of  lymphocytes to M. leprae  as well as pro-inflammatory cytokines such as 
IL-1, IL-2, IL-12, IFN- and TNF 
 
 The specific role of T cells in RR is unknown. 
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Box 2: Erythema Nodosum Leprosum (ENL) 
 
 Affects 20% of LL and 10% of BL patients. High bacterial load and greater 
infiltration of lesions as important risk factors. 
 
 Painful and tender red papules or nodules which may be accompanied by fever, joint 
pain, oedema of the hands, feet, and face, proteinuria and malaise. Neuritis is usually 
milder than with RR. 
 
 Immune complex mediated disease with some degree of CMI. Histologically 
characterized by neutrophils followed by increased number of lymphocytes, plasma 
cells and histiocytes. Vasculitis appears to be a major pathological event along with 
interstitial oedema and necrotizing changes 
 
 Recruitment of immune cells into the lesional sites and their activation is largely 
effected through the various soluble molecules such as cytokines, chemokines and 
immune complexes. 
 
 The antigen specific function of T cell is ill defined. 
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Photomicrography 1: Characterization of cellular infiltrate in leprosy lesions. HE: Hematoxilin Eosin. Magnification: 100x (except 1D: 400x) 
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Figure 1:  Summarized Immunohistopathology of Leprosy Spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 43 
 
Figure 2: Biomarkers of Innate Response to M. leprae Infection. Abreviations: (AA: 
Arachidonic  Acid; AGP: Alpha 1 Acid Glycoprotein; ApoB: apolipoprotein B; APP: Acute 
phase protein; EPA: eicosapentaenoic acid; CRP: C reactive protein; IDO: indoleamine 2 3-
dioxygenase; IL-6: Interleukin-6; IL-12: Interleukin-12; iNOS: Inducible nitric oxide synthase; 
LILR’s: leukocyte immunoglobulin-like receptors; MBL: mannose binding protein; PEIPC (1-
palmitoyl-2-(5,6-epoxyisoprostane E2)-snglycero-3-phosphoryl choline); PUFA’s: 
Polyunsaturated Fatty Acids; SAA: Serum amyloid A; sIL-6R: soluble  interleukin-6 receptor;  
sTREM-1: soluble triggering receptor expressed on myeloid cells 1; TLR: Toll like receptor; 
TNF-α: Tumor necrosis factors alfa; TREM-1: Triggering receptor expressed on myeloid cells 1; 
VitD: Vitamin D. Molecules of particular interest are highlighted. 
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Figure 3: Acquired Immune responses to Leprosy. The key players are highlighted.  
 
 
